SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could fall after early 2027 is driving the sharp selloff, raising concerns about pricing and CorMedixs largest revenue stream. Traders disagree over how much weight to give DaVitas preliminary outlook versus CMSs stated Q1 rate, with some calling the drop an overreaction and others questioning managements response and capital allocation.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of a competing treatment for recurrent respiratory papillomatosis has raised concerns about competition for Precigens PAPZIMEOS and triggered a sharp selloff. Traders debate whether the rival can erode PAPZIMEOS uptake or whether Precigens full approval, commercial head start, and established sales offer an advantage.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disneys latest quarterly results, supported by resilient theme-park performance and improving streaming profitability, have encouraged bullish reactions and analyst upgrades. Traders remain divided, with some seeing a recovery setup while others question whether the shares can sustain a move higher after years of range-bound performance.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinias Q3 results and higher full-year revenue guidance are driving discussion, with traders pointing to continued LUPKYNIS growth and solid execution. Reactions are mixed: many view the report positively, while others are frustrated by the share-price decline and uncertainty over an earnings call; patent litigation and pipeline speculation are secondary topics.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visas fiscal fourth-quarter results beat expectations, with resilient payment and cross-border activity, but traders are debating whether slower-growth guidance and a rich valuation temper the strong operating performance; reactions include sell-the-news caution alongside longer-term optimism.

Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The firm operates as a digital asset treasury company which focuses on the Hyperliquid ecosystem. The company was founded on July 2, 2025 and is headquartered in New York, NY.

Hyperliquid Strategies Inc.

PURR is drawing attention as a listed treasury vehicle tied to Hyperliquids HYPE token, with traders reacting to HYPEs rally to record levels while debating why PURR has lagged. Bulls point to its HYPE exposure and possible short-covering; bears cite potential dilution from share issuance and volatile price action.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomms sharp decline is being discussed mainly as part of a broad semiconductor selloff linked by traders to Intels weak outlook, with some also pointing to Qualcomm-specific licensing costs and upcoming earnings uncertainty. Reactions are split between dip buyers who view the drop as sector-driven and holders concerned about the stocks continued weakness.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels weak fourth-quarter outlook, amid softer PC demand and manufacturing constraints, triggered a sharp selloff and analyst downgrades. Traders are divided between calling the drop an overreaction and buying the dip, and expecting further losses while questioning managements execution and the turnaround.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellass REGAL Phase 3 AML trial reached its prespecified 80th death event, triggering final analysis ahead of topline results. Traders are debating whether GPS improved survival versus best available treatment: bullish holders see reasons for optimism, while skeptics cite dosing changes and possible effects from transplants or censoring; the share-price decline after the milestone has sharpened that disagreement.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ais quarterly results are driving discussion: despite an adjusted EPS beat and positive free cash flow, revenue remained sharply lower year over year and the next-quarter outlook disappointed traders. The community is split between viewing stronger bookings and restructuring as signs of a turnaround and focusing on weak growth and continued losses; short-squeeze chatter is also prominent.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

 Wag! Group Stock Jumps After-Hours As Board Weighs Strategic Moves: Retail Bulls Pounce

Equity

The company has not set a timeline for the conclusion of this review process.

Wag Group Co. engages in the development of a proprietary marketplace technology, which enables independent pet caregivers to connect with pet parents for specific pet care services. The company was founded in 2015 and is headquartered in San Francisco, CA.

Wag Group Co

Neutral Sentiment

Shares of Wag! Group Co. (PET) rose more than 4% in after-hours trading after the company said its board is reviewing strategic alternatives, including potential investments, partnerships, sale, or merger.“Our Board and management team continues to believe in the strength of our business, the effectiveness of our strategic plan, and our ability to execute on our strategy to drive value for shareholders,” said CEO and Chairman Garrett Smallwood.“We remain focused on strengthening our balance sheet and reducing our debt. Our board is committed to a disciplined and deliberate approach to ensure the best outcome for our shareholders."The company has not set a timeline for the conclusion of this review process.Sentiment on Stocktwits increased in the extremely bullish zone. Message volume climbed to the ‘extremely high’ zone from ‘high.’<figure class="image"><img style="aspect-ratio:1308/326;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_25_at_9_03_49_AM_png_09a34e63f4.webp" alt="Screenshot 2025-03-25 at 9.03.49 AM.png" width="1308" height="326"><figcaption>PET sentiment meter and message volume on March 24 as of 8:30 pm ET</figcaption></figure>Wag also posted its fiscal fourth quarter results on Monday that came below Wall Street expectations, posting a wider loss per share of $0.10 per share compared to the expected loss per share of $0.08.Fourth quarter revenues stood at &nbsp;$15.4 million compared to $21.7 million in the year-ago period. The Q4 figure was below the $15.8 million quoted by analysts.It posted Q4 net loss at $4.8 million, compared to $3.5 million in the fourth quarter of 2023.For 2025, Wag has projected revenue to be in the range of $84 million and $88 million.The company’s management highlighted the addition of three major new distribution partners, and its plans to use AI and boost strategic partnerships.Wag stock is down 18% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image. Source: Getty Images

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

PET Wag Group Co

Latest PET News